Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 3/20 | 0.52 |
| ▸ | ESR1 | P03372 | 2/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.42 |
| ▸ | ALB | P02768 | 1/20 | 0.42 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 2/20 | 0.40 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.40 |
| ▸ | ITGAV | P06756 | 1/20 | 0.40 |
| ▸ | THRA | P10827 | 1/20 | 0.40 |
| ▸ | RXRA | P19793 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13474000 | 0.91 | PTGS1 (0.44) | TTRESR1TRPA1ALBHSPA5 | |
| SCHEMBL6833615 | 0.83 | HSPA5 (0.62) | HSPA5MEN1LMNAKMT2AHTT | |
| SCHEMBL23921372 | 0.82 | TRPV1 (0.39) | TTRESR1THRBITGB3ITGAV | |
| SCHEMBL5884087 | 0.82 | ERN1 (0.58) | TTRESR1THRBITGB3ITGAV | |
| SCHEMBL14264005 | 0.82 | THRB (0.66) | TTRTHRBITGB3ITGAVTHRA | |
| SCHEMBL13019661 | 0.80 | PTGS2 (0.37) | TRPA1HSPA5RXRAPTGS2TBXA2R | |
| SCHEMBL12514479 | 0.79 | TTR (0.48) | TTRESR1ALBTHRBITGB3 | |
| Hydrochloric Acid SCHEMBL11251767 | 0.79 | HSPA5 (0.38) | TTRESR1HSPA5THRBITGB3 | |
| SCHEMBL18888072 | 0.79 | CHEK1 (0.56) | TTRESR1TRPA1ALBHSPA5 | |
| SCHEMBL13819754 | 0.78 | PTGS2 (0.36) | TRPA1PTGS2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3400229-B1 | 18/19F-LABELLED COMPOUNDS WHICH TARGET THE PROSTATE SPECIFIC MEMBRANE ANTIGEN | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2024-03-06 | — | — | EP | disclosed |
| US-20230296982-A1 | POLYMER, COMPOSITION, METHOD FOR PRODUCING POLYMER, COMPOSITION, COMPOSITION FOR FILM FORMATION, RESIST COMPOSITION, RADIATION-SENSITIVE COMPOSITION, COMPOSITION FOR UNDERLAYER FILM FORMATION FOR LITHOGRAPHY, RESIST PATTERN FORMATION METHOD, METHOD FOR PRODUCING UNDERLAYER FILM FOR LITHOGRAPHY, CIRCUIT PATTERN FORMATION METHOD, AND COMPOSITION FOR OPTICAL MEMBER FORMATION | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2023-09-21 | — | — | US | disclosed |
| US-20230114807-A1 | RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2023-04-13 | — | — | US | disclosed |
| US-9731016-B2 | Tyrosine-based lipids for delivery of therapeutics | MARINA BIOTECH, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| WO-2017117687-A1 | 18/19F-LABELLED COMPOUNDS WHICH TARGET THE PROSTATE SPECIFIC MEMBRANE ANTIGEN | BRITISH COLUMBIA CANCER AGENCY BRANCH (CA) | 2017-07-13 | — | — | WO | disclosed |
| US-20160206739-A1 | TYROSINE-BASED LIPIDS FOR DELIVERY OF THERAPEUTICS | MARINA BIOTECH INC (US) | 2016-07-21 | — | — | US | disclosed |
| US-9339461-B2 | Arginine-based lipids for delivery of therapeutics | MARINA BIOTECH, INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-20150209283-A1 | PROCESSES AND COMPOSITIONS FOR LIPOSOMAL AND EFFICIENT DELIVERY OF GENE SILENCING THERAPEUTICS | MARINA BIOTECH INC (US) | 2015-07-30 | — | — | US | disclosed |
| US-20150202175-A1 | Nitric Oxide Amino Acid Esters for Improving Vascular Circulation, and Prophylaxis or Treatment of a Condition Associated with Impaired Blood Circulation | FARBER MICHAEL (US) | 2015-07-23 | — | — | US | disclosed |
| US-9040706-B2 | Pyrrolidine inhibitors of IAP | GENENTECH, INC. (US) | 2015-05-26 | — | — | US | disclosed |
| US-7345081-B2 | Azabicyclo-octane inhibitors of IAP | GENENTECH, INC. (US) | 2008-03-18 | — | — | US | disclosed |
| US-20070299052-A1 | Inhibitors of IAP | GENENTECH, INC. (US) | 2007-12-27 | — | — | US | disclosed |
| US-20070299052-A1 | Inhibitors of IAP | GENENTECH, INC. (US) | 2007-12-27 | — | — | US | disclosed |
| US-7244851-B2 | 1-[2-Cyclohexyl-2-(2-methylamino-propionylamino)-acetyl]-pyrrolidine-2-carboxylic acid (2-phenyl-2H-pyrazol-3-yl)-amide; inhibitors of IAP, for treating malignancies | GENENTECH, INC. (US) | 2007-07-17 | — | — | US | disclosed |
| US-7244851-B2 | 1-[2-Cyclohexyl-2-(2-methylamino-propionylamino)-acetyl]-pyrrolidine-2-carboxylic acid (2-phenyl-2H-pyrazol-3-yl)-amide; inhibitors of IAP, for treating malignancies | GENENTECH, INC. (US) | 2007-07-17 | — | — | US | disclosed |
| WO-2007017284-A2 | INHIBITORS OF CANCER CELL, T-CELL AND KERATINOCYTE PROLIFERATION | 4SC AG (DE) | 2007-02-15 | — | — | WO | disclosed |
| US-20070037753-A1 | Inhibitors of cancer cell, T-cell and keratinocyte proliferation | 4SC AG (DE) | 2007-02-15 | — | — | US | disclosed |
| EP-1752467-A1 | Inhibitors of cancer cell, t-cell and keratinocyte proliferation | 4SC AG (DE) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005042530-A1 | RSV POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2005-05-12 | — | — | WO | disclosed |
| US-20040082578-A1 | Arylindenopyridines and related therapeutic and prophylactic methods | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150202175-A1 | Nitric Oxide Amino Acid Esters for Improving Vascular Circulation, and Prophylaxis or Treatment of a Condition Associated with Impaired Blood Circulation | NOS1, NOS2, NOS3 | TTR 379/4885ESR1 1505/4885TRPA1 1577/4885 |
| US-20070037753-A1 | Inhibitors of cancer cell, T-cell and keratinocyte proliferation | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, EGFR, MKI67 | TTR 3073/4885ESR1 2843/4885TRPA1 797/4885 |
| US-20160206739-A1 | TYROSINE-BASED LIPIDS FOR DELIVERY OF THERAPEUTICS | ABL1, LCK, ERBB2 | TTR 372/4885ESR1 2952/4885TRPA1 4657/4885 |
| US-20040082578-A1 | Arylindenopyridines and related therapeutic and prophylactic methods | ADORA2A, ADORA1, PDE2A | TTR 4018/4885ESR1 2423/4885TRPA1 322/4885 |
| US-20070299052-A1 | Inhibitors of IAP | XIAP, BIRC5, BIRC3 | TTR 3278/4885ESR1 2208/4885TRPA1 4514/4885 |
| US-20150209283-A1 | PROCESSES AND COMPOSITIONS FOR LIPOSOMAL AND EFFICIENT DELIVERY OF GENE SILENCING THERAPEUTICS | SLC27A2, LYPLA2, SLC27A1 | TTR 2996/4885ESR1 3767/4885TRPA1 1844/4885 |
| US-20230114807-A1 | RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN | FOLH1, KLK3, PSMA3 | TTR 3766/4885ESR1 29/4885TRPA1 747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.